MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
6.90
-0.45
-6.12%
Closed 19:37 02/28 EST
OPEN
7.30
PREV CLOSE
7.35
HIGH
7.32
LOW
6.87
VOLUME
331.01K
TURNOVER
0
52 WEEK HIGH
7.87
52 WEEK LOW
2.210
MARKET CAP
170.94M
P/E (TTM)
-3.4088
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ABEO last week (0219-0223)?
Weekly Report · 3d ago
Weekly Report: what happened at ABEO last week (0212-0216)?
Weekly Report · 02/19 11:36
Weekly Report: what happened at ABEO last week (0205-0209)?
Weekly Report · 02/12 11:25
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates confidence or concern around the company's prospects. The Dow Jones index closed higher by around 150 points on Wednesday. Recent notable insider transactions for penny stocks include Abeona Therapeutics and OPKO Health. Processa Pharmaceuticals, Inc. Is one of the companies with recent insider transactions.
Benzinga · 02/08 14:41
Wednesday 2/7 Insider Buying Report: ABEO, AFL
NASDAQ · 02/07 19:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
ThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. Femasys shares increased by 21.51% and PepGen stock rose 13.77% during the same time period. Losers include CytoMed Therapeutics and Cingulate.
Benzinga · 02/07 17:31
Abeona Therapeutics says CEO Seshadri buys 20K shares
Seeking Alpha · 02/07 15:31
Weekly Report: what happened at ABEO last week (0129-0202)?
Weekly Report · 02/05 11:34
More
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is EB-101, an autologous, engineered cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB). Its development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with unmet medical needs. The Company’s next generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility produced EB-101 for the pivotal Phase III VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. EB-101 is an autologous, engineered cell therapy in which a functioning COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) using a retrovirus.

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.